Thomas J. Moore - Publications, H-index & Citations

Thomas J. Moore

Johns Hopkins University

52H指数

213论文数

2.5W被引数

收录论文 45

发表时间

Developing New Drugs for the COVID-19 Emergency: Anatomy of the U.S. Response 为COVID-19紧急情况开发新药：美国应对措施剖析

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

IF0

2025-10-22

OAAI

Thomas J. Moore; Mariana P. Socal; Gerard Anderson

False or Misleading Claims in Online Direct-to-Consumer Ketamine Advertising in Maryland

JAMA NETWORK OPEN

IF9.7

2023-11-07

OAAI

Crane, Matthew A.; DiStefano, Michael J.; Moore, Thomas J.

Inclusion of Participants with CKD and Other Kidney-Related Considerations during Clinical Drug Development Landscape Analysis of Anticancer Agents Approved from 2015 to 2019 在2019年批准的抗癌药物的临床药物开发前景分析中纳入患有CKD和其他肾脏相关考虑因素的参与者2015年

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

IF7.1

2023-03-06

OAAI

Butrovich, Morgan A.; Reaves, Allison C.; Heyward, Jamie; Moore, Thomas J.; Alexander, G. Caleb; Inker, Lesley A.; Nolin, Thomas D.

Retrospective analysis of chest drain size and complications in spontaneous secondary pneumothorax in a District General Hospital, UK

EUROPEAN RESPIRATORY JOURNAL

IF21

2022-12-01

PREAI

Moore, T.; Purcell, M.; Patel, K.; Steele, K.

Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease

NEUROLOGY

IF8.5

2021-09-28

PREAI

Hwang, Y. Joseph; Alexander, G. Caleb; An, Huijun; Moore, Thomas J.; Mehta, Hemalkumar B.

Association of Pharmaceutical Industry Payments to Physicians With Prescription and Medicare Expenditures for Pimavanserin

PSYCHIATRIC SERVICES

IF3.2

2021-01-01

PREAI

Mehta, Hemalkumar B.; Moore, Thomas J.; Alexander, G. Caleb

Key Evidence Supporting Prescription Opioids Approved by the US Food and Drug Administration, 1997 to 2018

ANNALS OF INTERNAL MEDICINE

IF15.2

2020-12-15

PREAI

Heyward, James; Moore, Thomas J.; Chen, Jennifer; Meek, Kristin; Lurie, Peter; Alexander, G. Caleb

US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS)

PHARMACEUTICAL MEDICINE

IF4.5

2020-03-16

PREAI

Moore, Thomas J.; Morrow, Richard L.; Dormuth, Colin R.; Mintzes, Barbara

The Fate of FDA Postapproval Studies

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2017-09-21

PREAI

Woloshin, Steven; Schwartz, Lisa M.; White, Brian; Moore, Thomas J.

The Harms of Antipsychotic Drugs: Evidence from Key Studies

DRUG SAFETY

IF3.8

2016-11-19

PREAI

Moore, Thomas J.; Furberg, Curt D.

FAULTY DEVICE AND RIVAROXABAN Optimal dosing of rivaroxaban is undefined

BMJ-BRITISH MEDICAL JOURNAL

IF42.7

2016-10-18

PREAI

Moore, Thomas J.

An ageing population and changing UK bacteraemia profile may affect the characteristics and microbiology of infective spondylodiscitis

JOURNAL OF INFECTION

IF11.9

2016-07-01

PREAI

Donovan, Joseph; Skittrall, Jordan P.; Moore, Thomas; Sargent, Catherine; Agranoff, Daniel; Llewelyn, Martin

Finasteride and the Uncertainties of Establishing Harms

JAMA DERMATOLOGY

IF11

2015-06-01

PREAI

Moore, Thomas J.

Electronic Health Data for Postmarket Surveillance: A Vision Not Realized

DRUG SAFETY

IF3.8

2015-05-30

OAAI

Moore, Thomas J.; Furberg, Curt D.

AGE AND THE RENAL BLOOD-SUPPLY - RENAL VASCULAR-RESPONSES TO ANGIOTENSIN-CONVERTING ENZYME-INHIBITION IN HEALTHY HUMANS

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

IF4.5

2015-04-27

PREAI

HOLLENBERG, NK; MOORE, TJ

Antidepressants increase, rather than decrease, risk of suicidal behaviours in younger patients

BMJ-BRITISH MEDICAL JOURNAL

IF42.7

2014-10-09

PREAI

Moore, Thomas J.

Dabigatran, bleeding, and the regulators

BMJ-BRITISH MEDICAL JOURNAL

IF42.7

2014-07-23

PREAI

Moore, Thomas J.; Cohen, Michael R.; Mattison, Donald R.

Expedited Review of New Drugs Reply

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

IF55

2013-01-16

PREAI

Moore, Thomas J.; Furberg, Curt D.

Underreporting of Hemorrhagic and Thrombotic Complications of Pharmaceuticals to the US Food and Drug Administration: Empirical Findings for Warfarin, Clopidogrel, Ticlopidine, and Thalidomide from the Southern Network on Adverse Reactions (SONAR)

SEMINARS IN THROMBOSIS AND HEMOSTASIS

IF4.1

2012-10-21

OAAI

Moore, Thomas J.; Bennett, Charles L.

The Safety Risks of Innovation The FDA's Expedited Drug Development Pathway

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

IF55

2012-09-05

PREAI

Moore, Thomas J.; Furberg, Curt D.

研究方向